Successful, we will reply to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

VX-702

HY-10401

(VX702; VX 702)

VX-702

VX-702 Chemical Structure

VX-702 is a highly selective inhibitor of p38α MAPK(IC50=4 -20 nM), 14-fold higher potency against the p38α versus p38β.

Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO $55 In-stock
10 mg $50 In-stock
50 mg $129 In-stock
100 mg $190 In-stock
200 mg Get quote
500 mg Get quote
Size Price Stock Quantity
Free sample   Apply now  
10 mM * 1 mL in DMSO €54 In-stock
10 mg €49 In-stock
50 mg €126 In-stock
100 mg €186 In-stock
200 mg Get quote
500 mg Get quote

* Please select Quantity before adding items.

Bulk Inquiry

Inquiry Information
Product name: VX-702
Cat. No.: HY-10401

VX-702 Data Sheet

  • View current batch:

    Purity: 99.54%

  • Network Version

    DataSheet

    Pdf Version Network Version

    MSDS

    Pdf Version

    COA

    Pdf Version

    NMR

    Pdf Version

    LCMS

Customer View

Related Compound Libraries

Biological Activity of VX-702

VX-702 is a highly selective inhibitor of p38α MAPK(IC50=4 -20 nM), 14-fold higher potency against the p38α versus p38β.
IC50 value: 4-20 nM [1]
Target: p38α MAPK
in vitro: Pre-incubation of platelets with VX-702 (1 μM) completely or partially inhibits p38 activation (IC50 4 to 20 nM) induced by platelet agonists including thrombin, SFLLRN, AYPGKF, U46619 and collagen. VX-702 shows no effect on platelet aggregation induced by any of the p38 MAPK agonists in the presence or absence of anti-platelet therapies [1]. VX-702 inhibits the production of IL-6, IL-1β and TNFα (IC50 = 59, 122 and 99 ng/mL, respectively) in a dose-dependent manner [2].
in vivo: The half-life of VX-702 is 16 to 20 hours, with a median clearance of 3.75 L/h and a volume of distribution of 73 L/kg. Both AUC and Cmax values are dose proportional for VX-702, which is predominantly cleared renally [2]. VX-702 (at a dose of 0.1 mg/kg twice daily) has an equivalent effect as that of methotrexate (0.1 mg/kg). In addition, VX-702 (5 mg/kg twice daily) also has an equivalent effect as prednisolone (10 mg/kg once daily), as measured by percentage inhibition of wrist joint erosion and inflammation score [3].

Protocol (Extracted from published papers and Only for reference)

More

Chemical Information

M.Wt 404.32 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C19H12F4N4O2
CAS No 745833-23-2
Solvent & Solubility

DMSO ≥78mg/mL Water <1.2mg/mL Ethanol ≥2.8mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 2.4733 mL 12.3664 mL 24.7329 mL
5 mM 0.4947 mL 2.4733 mL 4.9466 mL
10 mM 0.2473 mL 1.2366 mL 2.4733 mL

References on VX-702

Inhibitor Kit

Related p38 MAPK Products

  • BMS-582949 hydrochloride

    BMS-582949 hydrochloride is a novel highly selective p38(alpha) MAPK inhibitor, inhibits p38(alpha) with IC50 of 13 nM.

  • Doramapimod

    Doramapimod (BIRB 796) is a highly selective p38(alpha) MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKC(alpha)/(beta)/(gamma).

  • Losmapimod

    Losmapimod (GW856553X; SB856553; GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38(alpha) and p38(beta), respectively.

  • LY2228820

    LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38(alpha)MAPK and p38(beta)MAPK were 7 nM and 3 nM, respectively).

  • p38 MAPK-IN-1

    p38 MAPK-IN-1 is a novel potent and selective inhibitor of p38 MAPK with IC50 of 68 nM, shows sustained levels, low clearance and good bioavailability.

  • PD 169316

    PD 169316 is a potent, cell-permeable and selective p38 MAP kinase inhibitor (IC50 = 89 nM).

  • PH-797804

  • SB 202190

    SB 202190 is a highly selective, potent and cell-permeable inhibitor of p38 MAP kinase with IC50 values of 50 nM and 100 nM for p38(alpha) and p38(beta) respectively; also showed slightly weaker activity for BRD4 (Kd=3.4 uM).

  • SB 239063

    SB 239063 is a potent and selective p38 MAPK inhibitor (IC50 = 44 nM for p38(alpha)). SB 239063 displays > 220-fold selectivity over ERK, JNK1 and other kinases; ~ 3-fold more selective than SB 203580.

  • SB 242235

    SB-242235 is a potent and selective p38 MAP kinase inhibitor with IC50 of 1.0 uM.

MORE